Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results	LEUKEMIA	2023
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials	ANNALS OF HEMATOLOGY	2023
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib	BLOOD CANCER JOURNAL	2023
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts	AMERICAN JOURNAL OF HEMATOLOGY	2023
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML	CANCER	2023
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study	CANCERS	2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey	JOURNAL OF CLINICAL MEDICINE	2023
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?	BRITISH JOURNAL OF HAEMATOLOGY	2023
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	LEUKEMIA & LYMPHOMA	2023
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA	HEMASPHERE	2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia	CANCER	2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)	JOURNAL OF CLINICAL ONCOLOGY	2023
Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients	ANNALS OF HEMATOLOGY	2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis	CANCERS	2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study	FRONTIERS IN PHARMACOLOGY	2023
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort	EUROPEAN JOURNAL OF HAEMATOLOGY	2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy		2023
A traffic light for TFR by lineage-specific MRD		2023
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort		2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib		2023